HeartBeam, Inc.

HeartBeam, Inc. is a U.S. medical technology company developing a portable, cable-free ECG platform that captures cardiac signals in three dimensions and synthesizes a 12-lead ECG. Its system is designed for ambulatory use outside the hospital, with an initial focus on arrhythmia assessment and longer-term expansion into broader cardiac monitoring and heart-attack detection.

1.45

1.41

— HeartBeam, Inc.
	%
Ambulatory ECG hardware	45% Portable, credit-card-sized ECG recording devices used by patients outside a healthcare facility.
ECG synthesis software	25% Software that converts 3D cardiac signals into a synthesized 12-lead ECG for clinical interpretation.
Clinical workflow software	10% Patient and physician-facing applications that support data capture, review, and clinical use.
Clinical validation and support	20% Studies, reference-site development, and educational support used to drive adoption and reimbursement.

HeartBeam sells into clinical users rather than mass consumer channels, with early targets including concierge...

Concierge and preventative cardiology practicesprimary
Buy the system to give patients access to a medical-grade ECG outside the clinic and to support premium care workflows.
Hospital cardiology departmentsprimary
Use the device for ambulatory monitoring and diagnostic support where a standard 12-lead ECG is not practical.
Hospital-at-home programssecondary
Adopt the product for remote cardiac assessment in home-based care settings.
Healthcare insurers and payerssecondary
May reimburse the system if HeartBeam proves clinical benefit and cost-effectiveness.
Clinical trial sponsors and research sitesemerging
Use the platform in studies where portable, high-fidelity ECG data is needed.

HeartBeam’s initial commercial focus is the United States, where it has already run multicenter clinical studies and...

•Initial commercial market is the United States
•Clinical studies were run across five U.S. hospital sites
•FDA clearance supports U.S. launch readiness
•International expansion is opportunistic, not yet the main focus
•Patent protection extends to several European and Asian markets

HeartBeam’s strategy is to build clinical evidence first, then use that evidence to support commercial adoption and...

Clinical validation and FDA-backed commercializationshort-term

Adoption depends on proving the system is clinically credible and usable in real-world settings.

Reference-site and physician adoptionshort-term

A small number of credible clinical sites can accelerate trust and reduce sales complexity.

Payer reimbursement pathwaymedium-term

Coverage would materially expand addressable demand and improve economics.

Platform expansion and partnershipslong-term

Broader product functionality and licensing can extend the technology beyond the initial device launch.

HeartBeam is still in an early commercialization stage, so its business depends on successful clinical validation,...

high

Additional capital requirement

The company expects to need more funding to complete development and support growth, which could be dilutive or unavailable.

Scope: Development, launch, and operating runway
Materiality: high

high

Regulatory and clinical trial risk

Commercialization depends on FDA clearance and continued positive clinical evidence; setbacks would delay launch and adoption.

Scope: 12L synthesis software and future product claims
Materiality: high

high

Reimbursement and market adoption risk

Initial targets may buy outside reimbursement, but broader scale likely requires payer coverage and proof of cost-effectiveness.

Scope: Concierge, hospital, and payer channels
Materiality: high

medium

Competitive pressure

Apple, AliveCor, Google and other medtech firms have greater resources, brand recognition, and distribution.

Scope: Ambulatory ECG and cardiac monitoring market
Materiality: high

medium

Cybersecurity and data integrity

The product handles sensitive health data, and breaches or data corruption could harm operations and reputation.

Scope: Patient data and cloud/workflow systems
Materiality: medium

Stock-based compensation

Affects operating expense and net loss

Milestone-based vesting estimates

Can accelerate or defer equity compensation expense

Future revenue recognition

Will affect revenue timing and gross margin presentation

Capital raise accounting

Dilution and financing cash flow

HeartBeam, Inc.

Additional capital requirement

Regulatory and clinical trial risk

Reimbursement and market adoption risk

Competitive pressure

Cybersecurity and data integrity

HeartSciences Inc.

Heartflow, Inc.

iRhythm Holdings, Inc.

Odyssey Health, Inc.

BioCardia, Inc.

Adagio Medical Holdings, Inc.